Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective open-label study of andexanet alfa in patients receiving a factor Xa inhibitor who require urgent surgery (ANNEXA-S)
2020-000374-21Phase 2Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Mar 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of andexanet alfa in anticoagulant reversal and None, sponsored by Alexion Pharmaceuticals. Primary endpoint: Effective intraoperative hemostasis. Started Mar 2020; status: completed.
02
Drugs
andexanet alfa
03
Conditions
anticoagulant reversal
Beyond the preview
Go deeper on 2020-000374-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000374-21.